VOLUME 10 • NUMBER 5–6
MAY–JUNE 2013 • SUPPLEMENT A
THE OFFICIAL PUBLICATION OF THE INTERNATIONAL SOCIETY FOR CNS CLINICAL TRIALS AND METHODOLOGY
IN THIS ISSUE
Defining a Clinically Meaningful Effect for the Design and
Interpretation of Randomized Controlled Trials
by Richard S. E. Keefe, PhD; Helena C. Kraemer, PhD;
Robert S. Epstein, MD, MS; Ellen Frank, PhD;
Ginger Haynes, PhD; Thomas P. Laughren, MD;
James McNulty, AbScB; Shelby D. Reed, PhD;
Juan Sanchez, MD; and Andrew C. Leon, PhD
Study Site Experiences and Attitudes toward Prospective
Assessments of Suicidal Ideation and Behavior in Clinical
Trials: Results of an Internet-based Survey
Adam Butler, PhD; Michelle Stewart, PhD; Larry Alphs, MD, PhD;
Phillip B. Chappell, MD; Douglas E. Feltner, MD;
William R. Lenderking, PhD; Atul R. Mahableshwarkar, MD;
Clare W. Makumi, PharmD, MBA; Sarah Dubrava, MS;
and the ISCTM Suicidal Ideation and Behavior Assessment
Working Group
How Can Registries Contribute to the Development and
Evaluation of CNS Therapeutics?
by Joanne B. Severe, MS, and Annette Stemhagen, DrPH, FISPE
A SUPPLEMENT TO